New drug combo for immunotherapy-resistant lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of an immunotherapy drug (TQB2450), a targeted therapy (anlotinib), and chemotherapy for people with advanced non-small cell lung cancer whose cancer stopped responding to prior immunotherapy. It aims to find a new option when the first treatment didn't work anymore.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called non-small cell lung cancer that is advanced (stage IIIB, IIIC, or stage IV) or has come back.
- You must have received immunotherapy (like a PD-1 or PD-L1 blocker) with chemotherapy for your first treatment, and your cancer got worse during or soon after that treatment.
- If you have non-squamous cell type, your tumor should not have certain gene changes (EGFR, ALK, ROS1).
- You need to have at least one tumor that can be measured on a scan.
- You must be between 18 and 75 years old and be in fairly good overall health (able to do daily activities with little help).
- You must provide a sample of your tumor (from a past biopsy or a new one) for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests TQB2450 (a new cancer medicine) added to chemotherapy, or along with an oral medicine called anlotinib, for stage II–IIIB non-small cell lung cancer. It may help shrink tumors and improve outcomes in people who are getting curative surgery and have not had prior cancer drug treatment.
This trial studies an oral targeted medicine (anlotinib) combined with an immunotherapy (checkpoint inhibitor) for lung cancer that did not respond to first-line chemo-immunotherapy. It may help shrink tumors and improve disease control after standard treatment has failed.
This trial tests a new combination of an immunotherapy drug (QL1706) with chemotherapy and a special radiation technique (Quad Shot) for people with advanced non-small cell lung cancer that has spread. The goal is to see if this combination can help control the cancer better than standard treatment.
This trial tests a new treatment that combines a drug called SYS6010 with an immunotherapy (Enlonstobart) compared to the usual immunotherapy plus chemo for advanced lung cancer. The goal is to see if this combo works better and helps people with PD-L1 positive lung cancer live longer and feel better.
This trial tests if anlotinib (a targeted therapy) can help prevent lung cancer from returning after surgery for patients whose tumors did not completely disappear after chemotherapy plus immunotherapy before surgery.
This study tests a new combination of drugs (SYHX2011, carboplatin, and an immunotherapy called enlonstobart) as the first treatment for advanced squamous lung cancer that is PD-L1 positive. The goal is to see if this combination helps shrink tumors and slow cancer growth.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.